Alto Neuroscience(US:ANRO) Prnewswireยท2025-07-28 12:45Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) due to allegations of misleading statements regarding the effectiveness of its product pipeline, ALTO-100 [1][2]. Group 1: Allegations - The lawsuit claims that during the class period, the defendants made materially false and misleading statements about ALTO-100's effectiveness in treating major depressive disorder [2]. - It is alleged that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to inflated business and financial prospects for Alto Neuroscience [2]. - Consequently, the company's public statements were deemed materially false and misleading throughout the relevant time frame [2]. Group 2: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [1]. - Shareholders are encouraged to register for the class action by September 19, 2025, to potentially be appointed as lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].